Results 1 to 10 of about 251,823 (301)

Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea [PDF]

Epidemiology and Health, 2022
OBJECTIVES In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to a passive adverse event reporting system, was launched to ...
Yunhyung Kwon, Insob Hwang, Mijeong Ko, Hyungjun Kim, Seontae Kim, Soon-Young Seo, Enhi Cho, Yeon-Kyeng Lee   +7 more
doaj   +1 more source

Neutralization Activity against SARS-CoV-2 Variants after Booster Vaccination in Populations without COVID-19: A Meta-Analysis

Vaccines, 2022
A number of SARS-CoV-2 variants that have evolved to have significant immune escape have emerged worldwide since the COVID-19 outbreak. The efficacy of prime vaccination is waning with the evolution of SARS-CoV-2, and the necessity of booster doses is ...
Haoyue Cheng, Zhicheng Peng, Shuting Si, Xialidan Alifu, Haibo Zhou, Peihan Chi, Yan Zhuang, Minjia Mo, Yunxian Yu   +8 more
doaj   +1 more source

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2

Vaccines, 2021
Coronavirus Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the global challenge. Reaching global herd immunity will help end the COVID-19 pandemic.
Tzu-Chuan Ho, Yi-Ming Arthur Chen, Hung-Pin Chan, Chin-Chuan Chang, Kuo-Pin Chuang, Che-Hsin Lee, Cheng-Hui Yuan, Yu-Chang Tyan, Ming-Hui Yang   +8 more
doaj   +1 more source

Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants

Vaccines, 2022
Safe and effective vaccines for Corona Virus Disease 2019 (COVID-19) can prevent the virus from infecting human populations and treat patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Xuesong Xu, Yi Hong, Erjing Chen, Yaping Wang, Biao Ma, Jiali Li, Wei Su, Yuxin Zhou, Mingzhou Zhang   +8 more
doaj   +1 more source

Immune Response of a Heterologous mRNA-1273 Second-Dose Immunization after a First Dose of ChadOx1 against SARS-CoV-2: A Cross-Sectional Study

Vaccines, 2022
Heterologous vaccination regimens could contribute to broadening vaccination coverage. To date, there is little evidence on the effectiveness of a combination of adenoviral COVID-19 vaccines with a second dose of mRNA vaccines.
Beatrice Albanesi, Alessandro Godono, Rosanna Irene Comoretto, Elena Casabona, Giuliano Curoso, Massimiliano Victor Leone, Nicolò Milanesio, Ilenia Mirra, Giulia Montrucchio, Fabrizia Pittaluga, Rossana Cavallo, Marco Clari, Catalina Ciocan   +12 more
doaj   +1 more source

Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study

Frontiers in Immunology, 2023
IntroductionThe differential immune responses after two additional BNT162b2 (BNT) booster doses between ChAdOx1 nCoV-10 (ChAd)-primed and BNT-primed groups have not been elucidated.
Wooho Sim, Hyunhye Kang, Hyunhye Kang, Jin Jung, Jin Jung, Jihyun Lee, Geon Young Ko, Hye-Sun Park, Jeewan Choi, Kinam Park, Eun-Jee Oh, Eun-Jee Oh   +11 more
doaj   +1 more source

Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study

Vaccines, 2021
In several countries, thrombotic events after vaccination with ChAdOx1 nCoV-19 have led to heterologous messenger RNA (mRNA) boosting. We tested the antibody response to SARS-CoV-2 spike protein four weeks after heterologous priming with the ChAdOx1 ...
Davide Firinu, Andrea Perra, Marcello Campagna, Roberto Littera, Federico Meloni, Francesca Sedda, Maria Conti, Giulia Costanzo, Monica Erbi, Gianmario Usai, Carlotta Locci, Mauro Giovanni Carta, Riccardo Cappai, Germano Orrù, Stefano Del Giacco, Ferdinando Coghe, Luchino Chessa   +16 more
doaj   +1 more source

One-Year Post-Vaccination Longitudinal Follow-Up of Quantitative SARS-CoV-2 Anti-Spike Total Antibodies in Health Care Professionals and Evaluation of Correlation with Surrogate Neutralization Test

Vaccines, 2023
Numerous vaccines have been generated to decrease the morbidity and mortality of COVID-19. This study aims to evaluate the immunogenicity of the heterologous boosts by BioNTech against homologous boosts by CoronaVac at three-month intervals in two health
Yesim Tuyji Tok, Rabia Can Sarinoglu, Seyhan Ordekci, Serife Yilmaz, Gunes Ozcolpan, Aysen Bayram, Okan Kadir Nohut, Ipek Kocer, Ufuk Hasdemir, Mert Ahmet Kuskucu, Dildar Konukoglu, Aysegul Gozalan, Kenan Midilli, Gulden Celik   +13 more
doaj   +1 more source

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations

Vaccines, 2022
Objective: A comparative analysis was performed to investigate the potential risk factors of Adverse Events Following Immunization (AEFI) after receiving different booster vaccines.
Yunhua Wei, Yan Wang, Jian Liu, Yan Zha, Yuqi Yang, Ni Li, Yalin Zhou, Jinli Zhu, Neil Roberts, Lin Liu, Yaying Li   +10 more
doaj   +1 more source

Protection against Different Genotypes of Newcastle Disease Viruses (NDV) Afforded by an Adenovirus-Vectored Fusion Protein and Live NDV Vaccines in Chickens

Vaccines, 2021
The efficacy of an adenovirus-vectored Newcastle disease virus (NDV) vaccine expressing the fusion (F) NDV protein (adeno-F) was evaluated against challenges with virulent heterologous and homologous NDV strains to the F protein.
Helena L. Ferreira, Patti J. Miller, David L. Suarez   +2 more
doaj   +1 more source